Mozambique

Our 9th Research Digest assembles 87 abstracts published from May through June 2019 that feature evidence from Botswana (6), Eswatini/Swaziland (2), Malawi (12), Mozambique (4), South Africa (46), Tanzania (4), Zambia (7) and Zimbabwe (17).

In our 8th issue of our Research Digest, we have assembled 64 abstracts published from March through April 2019 that feature evidence from Botswana (2), Eswatini (2), Lesotho (2), Malawi (12), Mozambique (4), Namibia (1), South Africa (32), Tanzania (3), Zambia (11) and Zimbabwe (14).

HIV test-and-treat programmes are being implemented throughout sub-Saharan Africa, enrolling HIV-positive clients into antiretroviral treatment (ART) immediately after diagnosis, regardless of clinical stage or CD4 count. This study conducted in Mozambique examined what influenced clients who tested HIV-positive in the context of test-and-treat to make ART initiation decisions.

Increasing numbers of people living with HIV (PLHIV) in sub-Saharan Africa are experiencing failure of first-line antiretroviral therapy and transitioning onto second-line regimens. However, there is a dearth of research on their treatment experiences. We conducted in-depth interviews with 43 PLHIV on second- or third-line antiretroviral therapy and 15 HIV health workers in Kenya, Malawi and Mozambique to explore patients' and health workers' perspectives on these transitions.

The voluntary medical male circumcision (VMMC) program in Mozambique aimed to increase male circumcision (MC) coverage to 80 percent among males ages 10 to 49 by 2018. Given the difficulty in attracting adult men over age 20 for circumcision, Mozambique became interested in assessing its age-targeting strategy and progress at the provincial level to inform program planning.

South Africa continues to bear a heavy burden of HIV and a significant proportion of the nation's population consists of immigrants from other severely afflicted African nations. Yet little is known about how migrant populations respond to HIV in shifting cultural and clinical landscapes.

Men's relatively low rates of HIV testing has been termed the 'HIV blind spot' and recently declared by UNAIDS as a top priority. This study uses data from five nationally representative Demographic and Health Surveys in Kenya, Malawi, Mozambique, Zambia, and Zimbabwe to explore factors associated with men's lifetime HIV testing.

In this, our 7th, issue, we have assembled 67 abstracts published from January through February 2019 that feature evidence from Botswana (3), Eswatini (2), Lesotho (2), Malawi (16), Mozambique (3), South Africa (40), Tanzania (2), Zambia (3) and Zimbabwe (7).